Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Ex-Drug Company Employees Accounts for 21 at PMDA
January 17, 2011
- Top-Leaders Stress Importance of Renovation in New Year's Addresses
January 17, 2011
- Mr Hasegawa to Lead Both KEIZAI DOYUKAI, Takeda
January 17, 2011
- BI Group to Inaugurate New Business Structure in Japan
January 17, 2011
- IBL to Develop Antibody Drugs Using Transgenic Silkworm
January 17, 2011
- Blopress Remains No. 1 for 7th Term in a Row: Domestic Drug Sales Ranking
January 17, 2011
- Mizuho Securities Lists Halaven, KW-0761 as Promising Anticancer Agents
January 17, 2011
- Pharma Industry Must Drive Nation's Economic Growth: Mr Matsuda
January 17, 2011
- Bayer, Regeneron Report Positive Results from 2 Studies on VEGF Trap-Eye
January 17, 2011
- Mr Matsutani Calls For Closer Cooperation with Makers to Settle Prices Quickly
January 17, 2011
- SymBio Starts PII Trial of Transdermal Antiemetic in Japan
January 17, 2011
- Morishita Jintan Merges Jintan Tech
January 17, 2011
- Prospects for Simultaneous Global Development: 3
January 17, 2011
- Addition of Noven Boosts Sales: Hisamitsu
January 17, 2011
- AnGes MG Granted Patent for NFκB Decoy Oligo
January 17, 2011
- Korosho to Accelerate Elimination of Drug-Lag: PS Okamoto
January 17, 2011
- JPA Opposed to Unification of Basic Dispensing Fees
January 17, 2011
- Korosho Considering PAL Amendment in 2012: Mr Masugi
January 17, 2011
- Korosho to Enhance Measures against ifestyle Diseases, Cancer, New-Types of Influenza
January 17, 2011
- Premium for New Drug Development Effective for Solving Drug-Lag Problem: MED Director
January 17, 2011
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…